FIT-039
目录号: PL04845 纯度: ≥98%
CAS No. :1113044-49-7
商品编号 规格 价格 会员价 是否有货 数量
PL04845-5mg 5mg ¥1112.73 请登录
PL04845-10mg 10mg ¥1854.55 请登录
PL04845-25mg 25mg ¥3709.09 请登录
PL04845-50mg 50mg 询价 询价
PL04845-100mg 100mg 询价 询价
PL04845-10mM*1mLinDMSO 10mM*1mLinDMSO ¥1224.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
FIT-039
中文别名
N-[5-氟-2-(1-哌啶基)苯基]-4-吡啶硫代甲酰胺;N-(5-氟-2-(哌啶-1-基)苯基)吡啶-4-碳硫酰胺;化合物FIT-039
英文名称
FIT-039
英文别名
FIT 039;FIT-039;FIT-039 (FIT039);4-Pyridinecarbothioamide, N-[5-fluoro-2-(1-piperidinyl)phenyl]-;N-(5-fluoro-2-(piperidin-1-yl)phenyl)pyridine-4-carbothioamide;N-[5-Fluoro-2-(1-piperidinyl)phenyl]-4-pyridinecarbothioamide
Cas No.
1113044-49-7
分子式
C17H18FN3S
分子量
315.41
包装储存
Powder -20°C 3 years;In solvent -80°C 6 months
产品详情
FIT-039 是一种选择性,ATP 竞争性且具有口服活性的 CDK9 抑制剂,对 CKD9/cyclin T1 的 IC50 为 5.8 μM。FIT-039 不抑制其他 CDK 和其他激酶。FIT-039 抑制 HSV-1 (IC50 为 0.69 μM),HSV-2,人腺病毒和人 CMV 的复制。FIT-039 是一种有前途的抗病毒剂,可用于抑制耐药性 HSV 和其他 DNA 病毒。
生物活性
FIT-039 is a selective, ATP-competitive and orally active CDK9 inhibitor with an IC 50 of 5.8 μM for CKD9/cyclin T1. FIT-039 does not inhibit other CDKs and other kinases. FIT-039 inhibits replication of HSV-1 (IC 50 of 0.69 μM), HSV-2, human adenovirus, and human CMV. FIT-039 is a promising antiviral agent for inhibiting drug-resistant HSVs and other DNA viruses.
性状
Solid
IC50 & Target[1][2]
CDK9/cyclinT1 5.8 μM (IC50) HSV-1 0.69 μM
体外研究(In Vitro)
FIT-039 (30 μM; 3 hours; HEK293 cells) treatment decreases phosphorylated CTD in the infected or noninfected cells to a level lower than that shown by Flavopiridol. FIT-039 reduces the expression levels of HSV-1 immediate-early genes (IEGs) and early and late genes.
FIT-039 inhibits replication of the HSV-1 genome in a dose-dependent manner (EC50 and EC80 are 0.69 μM and 4.0 μM, respectively).
FIT-039 potently suppresses 8 kinases (GSK3β, PKN1, haspin, p70s6K, DYRK1B, GSK3α, IRR, and DYRK3) other than CDK9 on the 332-kinase panel. These kinases are involved in the replication of various viruses. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Treatment with the FIT-039 ointment twice a day suppresses skin lesions and rescues mice (male BALB/c mice injected with HSV-1) from lethality in a dose-dependent manner. The healing of lesions is observed with 5% to 10% FIT-039 ointment, leading to the complete regression of zosteriform spread on day 10, which is also observed with the 5% ACV ointment.
FIT-039 does not affect body weight gain in mice administrated with an overdose of this compound (1000 mg/kg/d) for 14 days, and no changes are observed in biological markers in their blood. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;In solvent -80°C 6 months
参考文献
[1]. Makoto Yamamoto, et al. CDK9 Inhibitor FIT-039 Prevents Replication of Multiple DNA Viruses. J Clin Invest. 2014 Aug;124(8):3479-88.
溶解度数据
In Vitro: DMSO : 100 mg/mL (317.05 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2